Breaking News
Get 45% Off 0
🌊 NVIDIA ripple effect: Track AI stocks' response to chip giant's earnings
Explore AI Stocks

Cigna, Express Script Deal To Continue Healthcare Reshuffle

By Zacks Investment ResearchStock MarketsMar 07, 2018 08:41PM ET
www.investing.com/analysis/cigna-express-script-deal-to-continue-healthcare-reshuffle-200296609
Cigna, Express Script Deal To Continue Healthcare Reshuffle
By Zacks Investment Research   |  Mar 07, 2018 08:41PM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
 
ESRX
0.00%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
CI
-0.79%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
ELV
+1.75%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
AET
0.00%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
CVS
+0.97%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
UNH
+1.07%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 

Cigna Corp. (NYSE:CI) has announced that it will buy Express Scripts Holding Co., (NASDAQ:ESRX) a pharmacy benefits provider and other medical servcies.

The deal, valued $67 billion, will be financed by a mix of cash and debt. It will be one of the biggest deals for Cigna.

What’s in the Offing for Cigna?

The deal is expected to be mutually beneficial, given that it would lead to a solid combination of Cigna’s strong position and expertise in the health benefits space with Express Scripts’ leading position in the pharmacy benefits market (PBM).

This combined entity would create a mammoth healthcare set-up with wide-ranging operations from sale of drugs to insurance cover.

The deal will add to Cigna’s scale and size and equip it to negotiate with drug manufacturers and pharmacies better. This would lower the cost of acquiring prescription drugs, enabling the company to share the savings in with its consumers by way of more customer-friendly insurance plans like enhanced frills or lower premium, thus ultimately leading to market-share gains.

Odds of the deals getting a clearance from regulators seem high, as it will be a vertical integration. Last year, Cigna’s merger with Anthem Inc. (NYSE:ANTM) was blocked by regulators last year, on concerns that the combination would stifle competition in the healthcare industry since both companies had overlapping businesses.

In a year’s time shares of the company have gained 28% compared with the industry’s growth of 8.2%.



Growing Trend of Health Insures Catching up with PBM

With this deal, Cigna will be catching up with the growing bandwagon of health insurers tying up with pharmacy benefits mangers. The acquisition of Aetna Inc. (NYSE:AET) , one of the nation’s leading health insurers, by pharmacy benefit major CVS Health Corp (NYSE:CVS). is already underway. Another deal in the same vein was the takeover of Catamaran by health insurer leader UnitedHealth Group Inc (NYSE:UNH)., in 2015.

Pharmacy benefit managers work primarily for insurers and employers and seek to negotiate drug prices with pharmaceutical companies and drugstores to reduce the pocket-pinch for consumers. This in turn lowers the medical cost for insurers.

Moreover, insurers seek an attractive business opportunity in the PBM market, which largely benefits from an aging population, which depends largely on drugs and pharmacy benefit plans. Per a report by Technavio, nearly 14.4% of the U.S. population is aged 65 years and above, which buoys optimism.

Many analysts believe that rising expenditure on prescription drugs and growing demand for specialty drugs have also been strengthening the PBM market. The Centers for Medicare and Medicaid Services report published by Advisory Board predicts the continuation of this trend. Per the report, prescription drug spending is projected to grow roughly 7% between 2018 and 2019.

Consolidation in Healthcare

Most economists believe this coming together of two different industries in the healthcare sector will add a new dimension and might help in checking soaring costs.

Moreover, necessitated by the need of the players to gain in scale and size to weather the changes taking place within the industry, mergers and acquisitions (both horizontal and vertical) are common. No matter whether a company wishes to grow horizontally (expand in the existing business) or vertically (expand into new business), the most sought-after way is to acquire the best fit.

Cigna carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

The Hottest Tech Mega-Trend of All

Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.

See Zacks' 3 Best Stocks to Play This Trend >>



Cigna Corporation (CI): Free Stock Analysis Report

Aetna Inc. (AET): Free Stock Analysis Report

Anthem, Inc. (ANTM): Free Stock Analysis Report

Express Scripts Holding Company (ESRX): Free Stock Analysis Report

Original post

Zacks Investment Research

Cigna, Express Script Deal To Continue Healthcare Reshuffle
 

Related Articles

Timothy Fries
Is Tesla on the Right Track in 2025? By Timothy Fries  - Feb 27, 2025 2

Since the Robotaxi event on October 11th, Tesla (NASDAQ:TSLA) stock is up 38%, currently priced at $291.60 per share This is a return to the early November 2024 price level. But...

Cigna, Express Script Deal To Continue Healthcare Reshuffle

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Apple
Continue with Google
or
Sign up with Email